From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

TPXimpact – “maintaining” adjusted EBITDA targets, but how realistic really are they now?

By Steve Moore | Tuesday 10 September 2024


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Most recently writing on ‘digital transformation’ provider to largely the UK public sector TPXimpact (TPX), in May with the shares up to 43.5p I questioned it reiterating previously-announced targets. So what of now a “Trading Update” including “maintaining its FY25 Adjusted EBITDA target of £7-8m… FY26, the board is maintaining its targets of like-for-like revenue growth of 10-15% and an Adjusted EBITDA margin of 10-12%. The board remains confident that the company is strongly positioned in its key markets, with significant opportunities in digital transformation and responsible AI” – and the shares currently approaching 6% down towards 40p?

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 11:37:05